NCT02304081View on ClinicalTrials.gov

Saxagliptin in Combination With Dapagliflozin - Effects on Islet Cell Function

PHASE4CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions
Type2 Diabetes Mellitus
Interventions
DRUG

Saxagliptin

competitive inhibitor of human dipepitdylpeptidase (DPP)-IV

DRUG

Placebo for Saxagliptin

Trial Locations (1)

55116

Profil Mainz GmbH & Co. KG, Mainz

All Listed Sponsors
lead

Prof. Dr. Thomas Forst

INDUSTRY

NCT02304081 - Saxagliptin in Combination With Dapagliflozin - Effects on Islet Cell Function | Biotech Hunter | Biotech Hunter